Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Zoticon BioVentures
AddedFeb 15, 2024
UpdatedJun 28, 2026
Zoticon BioVentures

Zoticon BioVentures

Zoticon, an Israel-based medical organization, invests in late-stage therapeutics, creating dedicated companies for focused drug development.

HQ
Rehovot, Central District, IL
Overview
Compare
Employees
Website

Founded in Rehovot, Central District, Israel, Zoticon BioVentures is a medical organization dedicated to investing in late-stage therapeutics. With a core mission to bring innovative drugs to patients, Zoticon focuses on phase III therapeutics, particularly in oncology and cardiovascular treatments. The company creates a new entity for each in-licensed asset, ensuring specialized and concentrated development efforts. Zoticon's vision is to advance medical treatments through strategic investments and dedicated development processes.

Zoticon has invested over $100 million to date, backed by solid financial institutions that share its commitment to medical innovation. Notable affiliated individuals include experienced professionals in the pharmaceutical and biotech industries. The company's key achievements include advancing two oncology products and a cardiovascular combination product through late-stage development. Zoticon's impact lies in its ability to bring promising therapeutics closer to market, potentially improving patient outcomes and contributing to medical advancements.

Zoticon BioVentures - Quick Facts

Where is Zoticon BioVentures' headquarters located?

Zoticon BioVentures' headquarters is located in Rehovot, Central District, IL.

How many employees does Zoticon BioVentures have?

Zoticon BioVentures has 50 employees as of Feb 4, 2024.

Zoticon BioVentures - Classification

Ownership
  • Private
Technology
  • Biotech
Geographic Exposure
  • Israel
Customer
  • Enterprise
Main Product
  • Drug Development
  • Therapeutics
Tags
  • Financial
  • Healthtech
NAICS
  • 620000Health Care and Social Assistance
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified